Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
St. Jude Children's Research Hospital
The Primary Objective of the study is to compare the research participant's GM \[Gray Matter\] CBF \[Cerebral Blood Flow\] by ASL \[Arterial Spin Labeling\] techniques before and after reaching a stable hydroxyurea MTD \[Maximum Tolerated Dose\] (12±3 months after starting hydroxyurea).
This is an observational study. Participants receive hydroxyurea as part of their standard of care treatment. This study will observe the above measures prior to beginning hydroxyurea and after participants reach the maximum tolerated dose in order to describe the effect of therapy on the participants' functional response.
Age
5–19
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. The diagnosis of HbSS or HbS/ß0-thalassemia
2. Age: 8.0 -- \<19 years old
1. The diagnosis of HbSS or HbS/ß0-thalassemia
2. Age: 8.0 -- \<19 years old
1. No diagnosis of HbSS or HbS/ß0-thalassemia
2. Age: 8.0 -- \<19 years old
You may not be if
1. Unable to tolerate the anatomical or fMRI \[functional magnetic resonance imaging\] without sedation or anesthesia
2. Currently receiving hydroxyurea therapy or transfusion therapy
3. Previous stem cell transplant or other myelosuppressive therapy
4. History of clinical stroke
5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent/assent.
1. Unable to tolerate anatomical or fMRI components without sedation or anesthesia
2. Currently receiving hydroxyurea or transfusion therapy
3. Previous stem cell transplant or other myelosuppressive therapy
4. History of clinical stroke
5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
1. Unable to tolerate anatomical or fMRI components without sedation or anesthesia
2. Currently receiving hydroxyurea or transfusion therapy
3. Previous stem cell transplant or other myelosuppressive therapy
4. History of clinical stroke
5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Clareo Health | State Of The Art Functional Imaging In Sickle Cell Disease
